Therapeutics News and Research

RSS

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

20 Aug 2010

Muscular Dystrophy Association awards $14.1M in new grants

The Muscular Dystrophy Association, which has invested almost $39 million in 2010 in worldwide research seeking treatments and cures for muscle diseases, today announced that it has awarded $14.1 million in new grants.

20 Aug 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.

20 Aug 2010

Trius Therapeutics second quarter 2010 revenue increases to $2.1 million

Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections, announced today its financial results for the three months ended June 30, 2010.

20 Aug 2010

Deficiencies in DNA loop formation can cause multiple diseases: Research

The genes that are responsible for maintaining each cell type form DNA loops that link control elements for these genes. This surprising genome structure is generated and reinforced by two essential protein complexes that bridge the loops and contribute to proper gene regulation.

19 Aug 2010

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $228,668 to Cognition Therapeutics (CogRx) to develop small molecule drugs that block the action of the toxic "oligomers" thought responsible for Alzheimer's disease (AD).

19 Aug 2010

MD Anderson Cancer Center receives $20 million to advance research on targeted therapies

Dallas businessman and philanthropist H. Ross Perot has donated $20 million to The University of Texas MD Anderson Cancer Center for research to advance and design novel targeted therapies.

19 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

18 Aug 2010

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

18 Aug 2010

Midatech Group, MonoSol Rx file patent to enable commercialization of drug delivery technology

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and MonoSol Rx, the leader in developing and manufacturing pharmaceutical films based on its proprietary PharmFilm drug delivery technology, today announced the filing of a provisional US patent application for "Nanoparticle Film Delivery Systems." The applications submitted to the United States Patent and Trademark Office (USPTO) relate to therapeutic uses of nanoparticle-based proteins and peptides delivered in pharmaceutical films.

18 Aug 2010

AMT's MAA for LPLD gene therapy product Glybera on schedule

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that the Marketing Authorisation Application (MAA) for Glybera(R) remains on schedule following meetings with the European Medicine Agency (EMA) concerning the Day 120 List of Questions. The company is confident that Glybera(R), a gene therapy product for lipoprotein lipase deficiency (LPLD), remains on track for a regulatory decision by mid-2011.

18 Aug 2010

Researchers discover sugars that fight body's natural defenses, vaccines

A special set of sugars found on some disease-causing pathogens helps those pathogens fight the body's natural defenses as well as vaccines, say two Iowa State University researchers.This discovery may be a first step in understanding a disease family that includes tuberculosis for which there are currently no good vaccines or cures.Nicola Pohl, professor of chemistry, and Christine Petersen, assistant professor of veterinary pathology, discovered that a natural coating of sugar interacts with the body's defense cells to dampen its own immune response.

18 Aug 2010

NCI grants SBIR award to MabVax Therapeutics

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP).

18 Aug 2010

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate is ZC-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease.

18 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

TRI awarded RSC contract to support domestic, international clinical research programs

Technical Resources International, Inc. is pleased to announce that TRI has been awarded the Regulatory Support Center contract by the U.S. National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health, Department of Health and Human Services.

17 Aug 2010

PRA International to host audio conference on CV drug development strategy

PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific Affairs unit, will be the presenter.

17 Aug 2010

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the August edition of Cancer Cell.

17 Aug 2010

Therapeutics News and Research

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Muscular Dystrophy Association awards $14.1M in new grants

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

Trius Therapeutics second quarter 2010 revenue increases to $2.1 million

Deficiencies in DNA loop formation can cause multiple diseases: Research

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

MD Anderson Cancer Center receives $20 million to advance research on targeted therapies

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Midatech Group, MonoSol Rx file patent to enable commercialization of drug delivery technology

AMT's MAA for LPLD gene therapy product Glybera on schedule

Researchers discover sugars that fight body's natural defenses, vaccines

NCI grants SBIR award to MabVax Therapeutics

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

TRI awarded RSC contract to support domestic, international clinical research programs

PRA International to host audio conference on CV drug development strategy

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News